CD4 and acute myeloid leukemia: To prevent recurrent disease after allogeneic HSCT, T cells engineered with TCRs against HLA-DPB1 antigens, which are mismatched in many allogeneic transplantations, recognized AML cells in vitro; however, only TCR-engineered CD4 T cells were able to effectively mediate leukemic elimination in vivo [113].